FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to application of a pharmaceutical drug form for peroral introduction to reduce inter-individual variability in paracetamol-containing compositions in a diabetic patient with gastric dismotility. The said drug form contains in a form of a granulate: paracetamol in amount 60-80 wt %, calcium carbonate in amount 5-20 wt %, at least, one first binding substance and, at least, one disintegrating substance, as well as, at least, one hydrophilic colloid as an extragranular component.
EFFECT: invention ensures improvement of an active substance absorption in the patient with gastric dismotility.
13 cl, 1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
IMMEDIATE RELEASE DOSAGE FORM | 2020 |
|
RU2795085C2 |
GLUCOSAMINE PROLONGED RELEASE DOSAGE FORM | 2011 |
|
RU2521231C2 |
SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING INTEGRASE INHIBITOR | 2010 |
|
RU2602865C2 |
NSAID PREPARATION CONTAINING GRANULATED COMPOSITION AND EXTRA-GRANULATED COMPOSITION | 2002 |
|
RU2298404C2 |
PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
ANTISENSE COMPOSITIONS AND METHODS FOR PRODUCTION AND USE THEREOF | 2009 |
|
RU2593939C2 |
CENICRIVIROC COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2633069C2 |
ANTISENSE COMPOSITIONS AND METHODS FOR PRODUCTION AND USE THEREOF | 2009 |
|
RU2739302C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATING DEMYELINIATING DISEASES | 2013 |
|
RU2530626C1 |
Authors
Dates
2014-05-27—Published
2009-07-29—Filed